Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy

Pediatr Infect Dis J. 2006 Jun;25(6):562-4. doi: 10.1097/01.inf.0000219401.70804.1a.

Abstract

We report 2 sisters with hyper-IgE syndrome treated with daily suppressive dosages of linezolid (LZD) who developed LZD-resistant Staphylococcus aureus carrying the G2576T mutation in the 23S rRNA gene. Molecular typing suggested transmission of the resistant strain from one sister to the other. LZD-susceptible S. aureus was isolated 2 months after LZD discontinuation. LZD-resistant S. aureus remains rare but may occur while receiving suppressive therapy.

Publication types

  • Case Reports
  • Research Support, N.I.H., Intramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acetamides / administration & dosage*
  • Adolescent
  • Child
  • Disease Susceptibility
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Resistance, Bacterial*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunocompromised Host*
  • Job Syndrome / diagnosis
  • Job Syndrome / immunology*
  • Linezolid
  • Microbial Sensitivity Tests
  • Oxazolidinones / administration & dosage*
  • Risk Assessment
  • Siblings
  • Staphylococcal Infections / diagnosis
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / isolation & purification
  • Treatment Outcome

Substances

  • Acetamides
  • Oxazolidinones
  • Linezolid